Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study
Reichert, Z.R., Morgan, T.M., Li, G., Castellanos, E., Snow, T., Dall’Olio, F.G., Madison, R.W., Fine, A.D., Oxnard, G.R., Graf, R.P., Stover, D.G.
Published in Annals of oncology (01.01.2023)
Published in Annals of oncology (01.01.2023)
Get full text
Journal Article
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
Rathkopf, D.E., Patel, M.R., Choudhury, A.D., Rasco, D., Lakhani, N., Hawley, J.E., Srinivas, S., Aparicio, A., Narayan, V., Runcie, K.D., Emamekhoo, H., Reichert, Z.R., Nguyen, M.H., Wells, A.L., Kandimalla, R., Liu, C., Suryawanshi, S., Han, J., Wu, J., Arora, V.K., Pourdehnad, M., Armstrong, A.J.
Published in Annals of oncology (16.09.2024)
Published in Annals of oncology (16.09.2024)
Get full text
Journal Article
CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
845PD - CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors
Antonarakis, E.S., Velho, P Isaacsson, Agarwal, N., Santos, V Sacristan, Maughan, B.L., Pili, R., Adra, N., Sternberg, C.N., Vlachostergios, P.J., Tagawa, S.T., Bryce, A.H., McNatty, A.L., Reichert, Z.R., Dreicer, R., Sartor, O., Lotan, T.L., Hussain, M.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing
Triner, D., Graf, R.P., Madison, R.W., Gjoerup, O., Tukachinsky, H., Ross, J.S., Quintanilha, J.C.F., Li, G., Cheng, H.H., Pritchard, C.C., Zurita, A.J., Qin, Q., Zhang, T., Agarwal, N., Reichert, Z.R., Mateo, J., Cieslik, M., Morgan, T.M.
Published in ESMO open (01.09.2024)
Published in ESMO open (01.09.2024)
Get full text
Journal Article